←HIMSHims & Hers HealthOur view: UnattractiveFull analysisעברית
Updated 17 Nov 2026
The company · 1 · Who is this company?

Hims & Hers runs an online clinic that mails treatments monthly

Online doctor visits

a licensed doctor or nurse writes the prescription in an app

Its own pharmacies

fill the order and mail it every month

2.79 million

subscribers in the US, Britain, Europe, Australia and Canada

People use it for things they would rather not raise with a family doctor, or that insurance will not pay for: hair loss, weight, skin, menopause and low testosterone.

The company · 2 · What exactly does it sell?

Most sales come from American subscribers

Each $1 of sales in Q3 2026, by where it was sold
74%26%
American subscribersClinics it bought abroad

At home it sells under the Hims and Hers brands. Abroad it bought online clinics in Britain, Australia and Canada. It reports no split by condition treated.

The company · 3 · How does it make money?

Customers pay every month until they cancel

$105paid by each subscriber a month in Q3 2026, against $81 a year earlier
57 centskept from each $1 after the drugs' cost, against 74 a year earlier
28 centsof each $1 of sales spent on marketing in Q3 2026

Billing is automatic each month, and a customer can cancel or pause between bills. Branded weight-loss drugs bring more money per customer but leave less of it behind.

Is it a good business? · 4 · What gives it an edge?

Two well-known brands and one app for many conditions

Hims and Hers

brands built with heavy advertising

13%

more subscribers than a year earlier

Someone who came for hair loss can add skin or weight care in the same app, so each subscriber pays more than a year ago.

Is it a good business? · 5 · What is the catch?

The drugs are not its own, and the makers sell them too

Lillysells the same weight-loss drugs to any patient at identical prices
Novo Nordisksued it over a patent in February 2026, then dropped the suit
LifeMD, Rorival apps offering the same care

Listed rivals: LLY · NVO · LFMD · AMZN

A customer can cancel any month and buy the same branded drug elsewhere, so the platform cannot charge more for the drug itself.

Is it a good business? · 6 · What does its record show?

Sales grew sixteenfold, but profit never got far above zero

Sales, $B
0.3
0.5
0.9
1.5
2.3
2.9
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$148.8M → $2,347.6Mrevenue, 2020 to 2025
Best year4.5%official profit per $1 in 2025, its best year
Now-8.1%official profit per $1 over the past year

Revenue grew every year. Profit turned positive in 2024 and 2025, then fell to a loss after the switch to branded weight-loss drugs and the purchase of clinics abroad.

Is it a good business? · 7 · How much room is there to grow?

One in eight American adults takes a weight-loss drug

12%of US adults taking a GLP-1 drug in late 2025
About 17%of them got it from an online provider
$2.2BHims & Hers' US revenue in 2025, across every condition

Most people still get these drugs from their own doctor. Nobody outside measures how much is spent buying them online, so the market in dollars is unknown.

Is it a good business? · 8 · Who is in charge?

The co-founder runs it and controls the votes

Andrew Dudumco-founder, chief executive and chairman since 2021
87.73%of the votes, through shares carrying 175 votes each
2027the year his performance pay is measured on sales and management's profit

Outside shareholders cannot outvote him. His pay targets use management's own profit measure, which leaves pay in shares out.

The story right now · 9 · How much do weight-loss drugs matter here?

Weight-loss drugs are its biggest bet, made by two companies

Lilly, Novo Nordiskmake the weight-loss drugs the app now sells
March 2026when it stopped selling its own copies of them

During the shortages it made its own copies of these drugs at lower prices. Now it sells the makers' branded drugs at the makers' prices, which brings in more per customer but keeps less.

The story right now · 10 · Why did profit fall when sales rose?

Reselling a branded drug leaves less behind than making your own

  1. It made its own copiesKept 74 cents of each $1 a year earlier.
  2. It switched to branded drugsMarch 2026, at the makers' prices.
  3. Each customer pays more$105 a month, up from $81.
  4. It keeps less of each dollar57 cents in Q3 2026, and a loss.

The maker sets the price and takes most of it, so a bigger bill does not mean a bigger profit. Lilly charges any patient the same as it charges on this app.

The story right now · 11 · What changed lately?

Sales jumped on bought clinics while profit turned to a loss

49%revenue growth in Q3 2026, against 21% in the US alone
$135Mof Q3 2026 revenue from Eucalyptus, bought in June
$33.0Mlost in Q3 2026, against a profit a year earlier

Weak quarter

Lilly's drugs join the app this quarter, and management expects another quarter of fewer subscribers. The next report, around 22 February 2027, shows whether customers come back.

The story right now · 12 · What is everyone arguing about?

Can a reseller of branded drugs earn real profit?

Many investors think

A fast grower sold off too far

We think

A busy clinic that keeps little of each sale and owes more than it holds

Against us: if scale cuts marketing and pharmacy costs and official profit passes 8% of sales, the business could earn into today's price.

The price and our view · 13 · What is a share worth?

The price sits above even our sunny future

$4.23what we think a share is worth
$4.23our value
Attractive
below $3.38
Unattractive
above $5.08
$1.41gloomy: growth half what analysts expect, thinner profit
$4.23our estimate: analysts' growth, profit back to its best
$16.05sunny: faster growth and profit twice its best year

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years, counting pay in shares as a cost and money owed as debt. Our rule: buy only at least a fifth below our estimate.

The price and our view · 14 · What if it all works?

As a bet on newer treatments, it is priced for success

Priced for successthe kind of bet this is
0.9×if it works
73%kept if it fails

Multiples of the company's value when the bet was last struck, 16 Nov 2026.

Valued alone, the established clinic covers less than today's price once its debts are paid, so success with testosterone and peptides adds little and failure costs a lot.

The price and our view · 15 · How could we be wrong?

Suppliers that compete, a lawsuit and money owed

The drug makersBiggest

Sell the same drugs directly.

The FTC lawsuitWatch

Over how subscriptions renew and cancel.

Money owedShowing now

About $1.2B more than its cash.

How many cancelUnknown

Not reported.

Rules on compounding, online prescribing and testosterone govern much of what it sells, and the founder controls the votes.

The price and our view · 16 · How will we know?

February's report shows whether customers come back

Subscribers growing again with Lilly's drugs on the appGood sign
Official profit passing 8% of salesGood sign
A 2027 profit forecast below 9% of sales on management's measureBad sign
FEB 202722

Fourth-quarter 2026 results, around 22 February 2027. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 17 · So, what do we think?

A fast-growing clinic at a price far above its worth

$4.23our value
Attractive
below $3.38
Unattractive
above $5.08

UnattractiveHigh conviction

Sales grow fast and each customer pays more, but it resells drugs the makers also sell, its best year earned little and it owes more than it holds. The price is about 439% of our value.

↑ ↓ to move · C for contents